@ ( @ % ) patients had disease-free survival events in the adjuvant capecitabine and oxaliplatin group versus @ ( @ % ) patients in the observation group ( stratified hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ ; p < @ ) .